Primary Graft Dysfunction

Yoshikazu Suzuki; Edward Cantu; Jason D. Christie

doi:10.1055/s-0033-1348474

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2013; 34(03): 305-319
DOI: 10.1055/s-0033-1348474

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Primary Graft Dysfunction

Yoshikazu Suzuki

¹Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

^*These authors have contributed equally to this work.

,

Edward Cantu

¹Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

^*These authors have contributed equally to this work.

,

Jason D. Christie

²Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

› Institutsangaben

Abstract

Primary graft dysfunction (PGD) is a syndrome encompassing a spectrum of mild to severe lung injury that occurs within the first 72 hours after lung transplantation. PGD is characterized by pulmonary edema with diffuse alveolar damage that manifests clinically as progressive hypoxemia with radiographic pulmonary infiltrates. In recent years, new knowledge has been generated on risks and mechanisms of PGD. Following ischemia and reperfusion, inflammatory and immunological injury-repair responses appear to be key controlling mechanisms. In addition, PGD has a significant impact on short- and long-term outcomes; therefore, the choice of donor organ is impacted by this potential adverse consequence. Improved methods of reducing PGD risk and efforts to safely expand the pool are being developed. Ex vivo lung perfusion is a strategy that may improve risk assessment and become a promising platform to implement treatment interventions to prevent PGD. This review details recent updates in the epidemiology, pathophysiology, molecular and genetic biomarkers, and state-of-the-art technical developments affecting PGD.

Keywords

primary graft dysfunction - lung transplantation - ischemia-reperfusion injury and repair - high-risk donor lung - ex vivo lung perfusion

Volltext

Referenzen

References
1 Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24 (10) 1454-1459
2 Christie JD, Van Raemdonck D, de Perrot M , et al; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods. J Heart Lung Transplant 2005; 24 (10) 1451-1453
3 Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc 2009; 6 (1) 39-46
4 Lee JC, Christie JD, Keshavjee S. Primary graft dysfunction: definition, risk factors, short- and long-term outcomes. Semin Respir Crit Care Med 2010; 31 (2) 161-171
5 Lee JC, Christie JD. Primary graft dysfunction. Clin Chest Med 2011; 32 (2) 279-293
6 Trulock EP. Lung transplantation. Am J Respir Crit Care Med 1997; 155 (3) 789-818
7 Christie JD, Bavaria JE, Palevsky HI , et al. Primary graft failure following lung transplantation. Chest 1998; 114 (1) 51-60
8 de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167 (4) 490-511
9 Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M, Ware LB. ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant 2005; 24 (10) 1483-1488
10 Khan SU, Salloum J, O'Donovan PB , et al. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response. Chest 1999; 116 (1) 187-194
11 King RC, Binns OA, Rodriguez F , et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69 (6) 1681-1685
12 Fiser SM, Tribble CG, Long SM , et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73 (4) 1041-1047 , discussion 1047–1048
13 Fisher AJ, Wardle J, Dark JH, Corris PA. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2002; 21 (11) 1206-1212
14 Thabut G, Vinatier I, Stern JB , et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002; 121 (6) 1876-1882
15 Chatila WM, Furukawa S, Gaughan JP, Criner GJ. Respiratory failure after lung transplantation. Chest 2003; 123 (1) 165-173
16 Christie JD, Kotloff RM, Pochettino A , et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124 (4) 1232-1241
17 Christie JD, Sager JS, Kimmel SE , et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127 (1) 161-165
18 Prekker ME, Herrington CS, Hertz MI, Radosevich DM, Dahlberg PS. Early Trends in PaO(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction. Chest 2007; 132 (3) 991-997
19 Oto T, Griffiths AP, Levvey BJ, Williams TJ, Snell GI. Unilateral radiographic abnormalities after bilateral lung transplantation: exclusion from the definition of primary graft dysfunction?. J Thorac Cardiovasc Surg 2006; 132 (6) 1441-1446
20 Oto T, Griffiths AP, Levvey BJ, Pilcher DV, Williams TJ, Snell GI. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg 2006; 132 (1) 140-147
21 Oto T, Levvey BJ, Snell GI. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant 2007; 26 (5) 431-436
22 Christie J, Keshavjee S, Orens J , et al; ISHLT Working Group on PGD. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant 2008; 27 (1) 138
23 Collins J. Imaging of the chest after lung transplantation. J Thorac Imaging 2002; 17 (2) 102-112
24 Anderson DC, Glazer HS, Semenkovich JW , et al. Lung transplant edema: chest radiography after lung transplantation—the first 10 days. Radiology 1995; 195 (1) 275-281
25 Kundu S, Herman SJ, Winton TL. Reperfusion edema after lung transplantation: radiographic manifestations. Radiology 1998; 206 (1) 75-80
26 Herman SJ, Rappaport DC, Weisbrod GL, Olscamp GC, Patterson GA, Cooper JD. Single-lung transplantation: imaging features. Radiology 1989; 170 (1 Pt 1) 89-93
27 Shah RJ, Diamond JM, Kawut SM , et al. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant 2012; 31 (9) 942-949
28 Christie JD, Kotloff RM, Ahya VN , et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171 (11) 1312-1316
29 Diamond JM, Lee JC, Kawut SM , et al; Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187 (5) 527-534
30 Prekker ME, Nath DS, Walker AR , et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006; 25 (4) 371-378
31 Christie JD, Bellamy S, Ware LB , et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010; 29 (11) 1231-1239
32 Kreisel D, Krupnick AS, Puri V , et al. Short- and long-term outcomes of 1000 adult lung transplant recipients at a single center. J Thorac Cardiovasc Surg 2011; 141 (1) 215-222
33 Daud SA, Yusen RD, Meyers BF , et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175 (5) 507-513
34 Huang HJ, Yusen RD, Meyers BF , et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant 2008; 8 (11) 2454-2462
35 Whitson BA, Prekker ME, Herrington CS , et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007; 26 (10) 1004-1011
36 Christie JD, Edwards LB, Kucheryavaya AY , et al; International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31 (10) 1073-1086
37 Shah RJ, Diamond JM, Kawut S , et al. Plasma RAGE levels measured 24 hours after lung transplantation are associated with bronchiolitis obliterans syndrome (BOS). Am J Transplant 2013; 13 (3) 754-759
38 Whitson BA, Nath DS, Johnson AC , et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006; 131 (1) 73-80
39 Kuntz CL, Hadjiliadis D, Ahya VN , et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant 2009; 23 (6) 819-830
40 de Perrot M, Bonser RS, Dark J , et al; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 2005; 24 (10) 1460-1467
41 Barr ML, Kawut SM, Whelan TP , et al; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 2005; 24 (10) 1468-1482
42 Fang A, Studer S, Kawut SM , et al; Lung Transplant Outcomes Group. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011; 139 (4) 782-787
43 Oto T, Griffiths AP, Levvey B , et al. A donor history of smoking affects early but not late outcome in lung transplantation. Transplantation 2004; 78 (4) 599-606
44 Kawut SM, Okun J, Shimbo D , et al; Lung Transplant Outcomes Group. Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 2009; 136 (1) 237-244
45 Sommers KE, Griffith BP, Hardesty RL, Keenan RJ. Early lung allograft function in twin recipients from the same donor: risk factor analysis. Ann Thorac Surg 1996; 62 (3) 784-790
46 Whelan TPM, Dunitz JM, Kelly RF , et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24 (9) 1269-1274
47 Cassivi SD, Meyers BF, Battafarano RJ , et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002; 74 (5) 1663-1669 , discussion 1669–1670
48 Fiser SM, Kron IL, McLendon Long S, Kaza AK, Kern JA, Tribble CG. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant 2001; 20 (6) 631-636
49 Lederer DJ, Kawut SM, Wickersham N , et al; Lung Transplant Outcomes Group. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011; 184 (9) 1055-1061
50 De Oliveira NC, Osaki S, Maloney J, Cornwell RD, Meyer KC. Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation. Interact Cardiovasc Thorac Surg 2012; 14 (3) 263-267
51 Nagendran M, Maruthappu M, Sugand K. Should double lung transplant be performed with or without cardiopulmonary bypass?. Interact Cardiovasc Thorac Surg 2011; 12 (5) 799-804
52 Dalibon N, Geffroy A, Moutafis M , et al. Use of cardiopulmonary bypass for lung transplantation: a 10-year experience. J Cardiothorac Vasc Anesth 2006; 20 (5) 668-672
53 Szeto WY, Kreisel D, Karakousis GC , et al. Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome. J Thorac Cardiovasc Surg 2002; 124 (2) 241-249
54 Aigner C. eComment: To pump or not to pump in lung transplantation—question solved?. Interact Cardiovasc Thorac Surg 2011; 12 (5) 805
55 Webert KE, Blajchman MA. Transfusion-related acute lung injury. Curr Opin Hematol 2005; 12 (6) 480-487
56 Silliman CC, Boshkov LK, Mehdizadehkashi Z , et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101 (2) 454-462
57 Silliman CC, Fung YL, Ball JB, Khan SY. Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev 2009; 23 (6) 245-255
58 Mangalmurti NS, Xiong Z, Hulver M , et al. Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation. Blood 2009; 113 (5) 1158-1166
59 Bonser RS, Taylor R, Collett D, Thomas HL, Dark JH, Neuberger J. Cardiothoracic Advisory Group to NHS Blood and Transplant and the Association of Lung Transplant Physicians (UK). Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet 2012; 380 (9843) 747-755
60 Eppinger MJ, Jones ML, Deeb GM, Bolling SF, Ward PA. Pattern of injury and the role of neutrophils in reperfusion injury of rat lung. J Surg Res 1995; 58 (6) 713-718
61 Eppinger MJ, Deeb GM, Bolling SF, Ward PA. Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol 1997; 150 (5) 1773-1784
62 Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Kron IL. Pulmonary macrophages are involved in reperfusion injury after lung transplantation. Ann Thorac Surg 2001; 71 (4) 1134-1138 , discussion 1138–1139
63 Naidu BV, Krishnadasan B, Farivar AS , et al. Early activation of the alveolar macrophage is critical to the development of lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2003; 126 (1) 200-207
64 Yang ZQ, Sharma AK, Linden J, Kron IL, Laubach VE. CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2009; 137 (3) 695-702 , discussion 702
65 van der Kaaij NP, Kluin J, Haitsma JJ , et al. Ischemia of the lung causes extensive long-term pulmonary injury: an experimental study. Respir Res 2008; 9: 28
66 Sharma AK, LaPar DJ, Zhao YG , et al. Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury. Am J Respir Crit Care Med 2011; 183 (11) 1539-1549
67 Johnston LK, Rims CR, Gill SE, McGuire JK, Manicone AM. Pulmonary macrophage subpopulations in the induction and resolution of acute lung injury. Am J Respir Cell Mol Biol 2012; 47 (4) 417-426
68 McCourtie AS, Merry HE, Farivar AS, Goss CH, Mulligan MS. Alveolar macrophage secretory products augment the response of rat pulmonary artery endothelial cells to hypoxia and reoxygenation. Ann Thorac Surg 2008; 85 (3) 1056-1060
69 McCourtie AS, Farivar AS, Woolley SM , et al. Alveolar macrophage secretory products effect type 2 pneumocytes undergoing hypoxia-reoxygenation. Ann Thorac Surg 2008; 86 (6) 1774-1779
70 Serrick C, Adoumie R, Giaid A, Shennib H. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994; 58 (11) 1158-1162
71 Mal H, Dehoux M, Sleiman C , et al. Early release of proinflammatory cytokines after lung transplantation. Chest 1998; 113 (3) 645-651
72 Fisher AJ, Donnelly SC, Hirani N , et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001; 163 (1) 259-265
73 Akashi A, Nakahara K, Kamiike W , et al. Attenuation of warm ischemic injury of rat lung by inflation with room air—assessment of cellular components and the surfactant in the bronchoalveolar lavage fluid in relation to changes in cellular adenosine triphosphate. Transplantation 1993; 55 (1) 24-30
74 Date H, Matsumura A, Manchester JK, Cooper JM, Lowry OH, Cooper JD. Changes in alveolar oxygen and carbon dioxide concentration and oxygen consumption during lung preservation: the maintenance of aerobic metabolism during lung preservation. J Thorac Cardiovasc Surg 1993; 105 (3) 492-501
75 Sakuma T, Takahashi K, Ohya N , et al. Ischemia-reperfusion lung injury in rabbits: mechanisms of injury and protection. Am J Physiol 1999; 276 (1 Pt 1) L137-L145
76 Fukuse T, Hirata T, Liu CJ, Hitomi S, Wada H. Energy metabolism and reperfusion injury in warm and cold ischemia of inflated and deflated lungs. Transplant Proc 2000; 32 (7) 2424-2425
77 Chatterjee S, Chapman KE, Fisher AB. Lung ischemia: a model for endothelial mechanotransduction. Cell Biochem Biophys 2008; 52 (3) 125-138
78 Browning EA, Chatterjee S, Fisher AB. Stop the flow: a paradigm for cell signaling mediated by reactive oxygen species in the pulmonary endothelium. Annu Rev Physiol 2012; 74: 403-424
79 Fisher AB, Al-Mehdi AB, Manevich Y. Shear stress and endothelial cell activation. Crit Care Med 2002; 30 (5, Suppl) S192-S197
80 Fukuse T, Hirata T, Ishikawa S , et al. Optimal alveolar oxygen concentration for cold storage of the lung. Transplantation 2001; 72 (2) 300-304
81 Van Raemdonck DE, Jannis NC, De Leyn PR, Flameng WJ, Lerut TE. Alveolar expansion itself but not continuous oxygen supply enhances postmortem preservation of pulmonary grafts. Eur J Cardiothorac Surg 1998; 13 (4) 431-440 , discussion 440–441
82 Rauen U, de Groot H. Mammalian cell injury induced by hypothermia- the emerging role for reactive oxygen species. Biol Chem 2002; 383 (3-4) 477-488
83 Burlingham WJ, Love RB, Jankowska-Gan E , et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117 (11) 3498-3506
84 Bharat A, Narayanan K, Street T , et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83 (2) 150-158
85 Bharat A, Kuo E, Steward N , et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008; 86 (1) 189-195 , discussion 196–197
86 Bharat A, Saini D, Steward N , et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 2010; 90 (4) 1094-1101
87 Pham SM, Yoshida Y, Aeba R , et al. Interleukin-6, a marker of preservation injury in clinical lung transplantation. J Heart Lung Transplant 1992; 11 (6) 1017-1024
88 Mathur A, Baz M, Staples ED , et al. Cytokine profile after lung transplantation: correlation with allograft injury. Ann Thorac Surg 2006; 81 (5) 1844-1849 , discussion 1849–1850
89 De Perrot M, Sekine Y, Fischer S , et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002; 165 (2) 211-215
90 Colombat M, Castier Y, Lesèche G , et al. Early expression of adhesion molecules after lung transplantation: evidence for a role of aggregated P-selectin-positive platelets in human primary graft failure. J Heart Lung Transplant 2004; 23 (9) 1087-1092
91 Abraham D, Taghavi S, Riml P , et al. VEGF-A and -C but not -B mediate increased vascular permeability in preserved lung grafts. Transplantation 2002; 73 (11) 1703-1706
92 Krenn K, Klepetko W, Taghavi S, Lang G, Schneider B, Aharinejad S. Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. Am J Transplant 2007; 7 (3) 700-706
93 Christie JD, Robinson N, Ware LB , et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007; 175 (1) 69-74
94 Covarrubias M, Ware LB, Kawut SM , et al; Lung Transplant Outcomes Group. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7 (11) 2573-2578
95 Bobadilla JL, Love RB, Jankowska-Gan E , et al. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008; 177 (6) 660-668
96 Iwata T, Philipovskiy A, Fisher AJ , et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181 (8) 5738-5747
97 Hoffman SA, Wang L, Shah CV , et al; Lung Transplant Outcomes Group. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant 2009; 9 (2) 389-396
98 Moreno I, Vicente R, Mir A , et al. Effects of inhaled nitric oxide on primary graft dysfunction in lung transplantation. Transplant Proc 2009; 41 (6) 2210-2212
99 Christie JD, Shah CV, Kawut SM , et al; Lung Transplant Outcomes Group. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180 (10) 1010-1015
100 Pelaez A, Force SD, Gal AA , et al. Receptor for advanced glycation end products in donor lungs is associated with primary graft dysfunction after lung transplantation. Am J Transplant 2010; 10 (4) 900-907
101 Salama M, Andrukhova O, Hoda MA , et al. Concomitant endothelin-1 overexpression in lung transplant donors and recipients predicts primary graft dysfunction. Am J Transplant 2010; 10 (3) 628-636
102 Diamond JM, Kawut SM, Lederer DJ , et al; Lung Transplant Outcomes Group. Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction. Am J Transplant 2011; 11 (3) 561-567
103 Diamond JM, Lederer DJ, Kawut SM , et al; Lung Transplant Outcomes Group. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. Am J Transplant 2011; 11 (11) 2517-2522
104 Diamond JM, Porteous MK, Cantu E , et al; Lung Transplant Outcomes Group. Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. PLoS ONE 2012; 7 (12) e51932
105 Bastarache JA, Diamond JM, Kawut SM, Lederer DJ, Ware LB, Christie JD. Postoperative estradiol levels associate with development of primary graft dysfunction in lung transplantation patients. Gend Med 2012; 9 (3) 154-165
106 Shah RJ, Diamond JM, Lederer DJ , et al. Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. Transl Res 2012; 160 (6) 435-442
107 Shah RJ, Bellamy SL, Localio AR , et al. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant 2012; 31 (9) 942-949
108 Taghavi S, Abraham D, Riml P , et al. Co-expression of endothelin-1 and vascular endothelial growth factor mediates increased vascular permeability in lung grafts before reperfusion. J Heart Lung Transplant 2002; 21 (5) 600-603
109 Kaneda H, Waddell TK, de Perrot M , et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006; 6 (3) 544-551
110 Ray M, Dharmarajan S, Freudenberg J, Zhang W, Patterson GA. Expression profiling of human donor lungs to understand primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7 (10) 2396-2405
111 Anraku M, Cameron MJ, Waddell TK , et al. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant 2008; 8 (10) 2140-2148
112 Hagedorn PH, Burton CM, Sahar E , et al. Integrative analysis correlates donor transcripts to recipient autoantibodies in primary graft dysfunction after lung transplantation. Immunology 2011; 132 (3) 394-400
113 Diamond JM, Meyer NJ, Feng R , et al; Lung Transplant Outcomes Group. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2012; 186 (6) 546-552
114 Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant 2005; 24 (10) 1489-1500
115 Van Raemdonck D, Neyrinck A, Verleden GM , et al. Lung donor selection and management. Proc Am Thorac Soc 2009; 6 (1) 28-38
116 de Perrot M, Keshavjee S. Lung preservation. Semin Thorac Cardiovasc Surg 2004; 16 (4) 300-308
117 Meade MO, Granton JT, Matte-Martyn A , et al; Toronto Lung Transplant Program. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003; 167 (11) 1483-1489
118 Botha P, Jeyakanthan M, Rao JN , et al. Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2007; 26 (11) 1199-1205
119 Keshavjee S, Davis RD, Zamora MR, de Perrot M, Patterson GA. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005; 129 (2) 423-428
120 Wittwer T, Grote M, Oppelt P, Franke U, Schaefers HJ, Wahlers T. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. J Heart Lung Transplant 2001; 20 (3) 358-363
121 Herrington CS, Prekker ME, Arrington AK , et al. A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation. Clin Transplant 2011; 25 (1) 90-96
122 Strüber M, Fischer S, Niedermeyer J , et al. Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial. J Thorac Cardiovasc Surg 2007; 133 (6) 1620-1625
123 Novick RJ, Stitt LW, Al-Kattan K , et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. Ann Thorac Surg 1998; 65 (1) 227-234
124 Currey J, Pilcher DV, Davies A , et al. Implementation of a management guideline aimed at minimizing the severity of primary graft dysfunction after lung transplant. J Thorac Cardiovasc Surg 2010; 139 (1) 154-161
125 Strüber M, Harringer W, Ernst M , et al. Inhaled nitric oxide as a prophylactic treatment against reperfusion injury of the lung. Thorac Cardiovasc Surg 1999; 47 (3) 179-182
126 Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996; 111 (5) 913-919
127 Adatia I, Lillehei C, Arnold JH , et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994; 57 (5) 1311-1318
128 Macdonald P, Mundy J, Rogers P , et al. Successful treatment of life-threatening acute reperfusion injury after lung transplantation with inhaled nitric oxide. J Thorac Cardiovasc Surg 1995; 110 (3) 861-863
129 Meyers BF, Sundt III TM, Henry S , et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000; 120 (1) 20-26
130 Glassman LR, Keenan RJ, Fabrizio MC , et al. Extracorporeal membrane oxygenation as an adjunct treatment for primary graft failure in adult lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110 (3) 723-726 , discussion 726–727
131 Hartwig MG, Appel III JZ, Cantu III E , et al. Improved results treating lung allograft failure with venovenous extracorporeal membrane oxygenation. Ann Thorac Surg 2005; 80 (5) 1872-1879 , discussion 1879–1880
132 Bermudez CA, Adusumilli PS, McCurry KR , et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: long-term survival. Ann Thorac Surg 2009; 87 (3) 854-860
133 Hartwig MG, Walczak R, Lin SS, Davis RD. Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation. Ann Thorac Surg 2012; 93 (2) 366-371
134 Naik PM, Angel LF. Special issues in the management and selection of the donor for lung transplantation. Semin Immunopathol 2011; 33 (2) 201-210
135 Kron IL, Tribble CG, Kern JA , et al. Successful transplantation of marginally acceptable thoracic organs. Ann Surg 1993; 217 (5) 518-522 , discussion 522–524
136 Sundaresan S, Semenkovich J, Ochoa L , et al. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 1995; 109 (6) 1075-1079 , discussion 1079–1080
137 Gabbay E, Williams TJ, Griffiths AP , et al. Maximizing the utilization of donor organs offered for lung transplantation. Am J Respir Crit Care Med 1999; 160 (1) 265-271
138 Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19 (12) 1199-1204
139 Straznicka M, Follette DM, Eisner MD, Roberts PF, Menza RL, Babcock WD. Aggressive management of lung donors classified as unacceptable: excellent recipient survival one year after transplantation. J Thorac Cardiovasc Surg 2002; 124 (2) 250-258
140 Pierre AF, Sekine Y, Hutcheon MA, Waddell TK, Keshavjee SH. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg 2002; 123 (3) 421-427 , discussion, 427–428
141 Lardinois D, Banysch M, Korom S , et al. Extended donor lungs: eleven years experience in a consecutive series. Eur J Cardiothorac Surg 2005; 27 (5) 762-767
142 Aigner C, Winkler G, Jaksch P , et al. Extended donor criteria for lung transplantation—a clinical reality. Eur J Cardiothorac Surg 2005; 27 (5) 757-761
143 Botha P, Trivedi D, Weir CJ , et al. Extended donor criteria in lung transplantation: impact on organ allocation. J Thorac Cardiovasc Surg 2006; 131 (5) 1154-1160
144 Meers C, Van Raemdonck D, Verleden GM , et al. The number of lung transplants can be safely doubled using extended criteria donors; a single-center review. Transpl Int 2010; 23 (6) 628-635
145 de Perrot M, Weder W, Patterson GA, Keshavjee S. Strategies to increase limited donor resources. Eur Respir J 2004; 23 (3) 477-482
146 Cypel M, Yeung JC, Liu MY , et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364 (15) 1431-1440
147 Cypel M, Yeung JC, Hirayama S , et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27 (12) 1319-1325
148 Steen S, Sjöberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357 (9259) 825-829
149 Lindstedt S, Hlebowicz J, Koul B , et al. Comparative outcome of double lung transplantation using conventional donor lungs and non-acceptable donor lungs reconditioned ex vivo. Interact Cardiovasc Thorac Surg 2011; 12 (2) 162-165
150 Cypel M, Yeung JC, Machuca T , et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg 2012; 144 (5) 1200-1206
151 Zych B, Popov AF, Stavri G , et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Heart Lung Transplant 2012; 31 (3) 274-281
152 Aigner C, Slama A, Hötzenecker K , et al. Clinical ex vivo lung perfusion—pushing the limits. Am J Transplant 2012; 12 (7) 1839-1847
153 Valenza F, Rosso L, Gatti S , et al. Extracorporeal lung perfusion and ventilation to improve donor lung function and increase the number of organs available for transplantation. Transplant Proc 2012; 44 (7) 1826-1829
154 Wallinder A, Ricksten SE, Hansson C , et al. Transplantation of initially rejected donor lungs after ex vivo lung perfusion. J Thorac Cardiovasc Surg 2012; 144 (5) 1222-1228
155 Cypel M, Liu M, Rubacha M , et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1 (4) ra9
156 Warnecke G, Moradiellos J, Tudorache I , et al. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. Lancet 2012; 380 (9856) 1851-1858